Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02935517
PHASE1/PHASE2

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

Sponsor: Beacon Therapeutics

View on ClinicalTrials.gov

Summary

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-402, administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGA3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

Official title: A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene

Key Details

Gender

All

Age Range

4 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2017-08-03

Completion Date

2026-08

Last Updated

2022-07-22

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

AGTC-402

AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Locations (6)

VitreoRetinal Associates

Gainesville, Florida, United States

Bascom Palmer Eye Institute

Miami, Florida, United States

Massachusetts Eye and Ear Infirmary

Boston, Massachusetts, United States

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Casey Eye Institute, Oregon Health and Sciences University

Portland, Oregon, United States

Hadassah-Hebrew University Medical Center

Jerusalem, Israel